Plant-based monoclonal antibody increases potency of antibody cocktail against SARS-CoV-2 Omicron variant Antibody Coronavirus Disease COVID Monoclonal Omicron ASU BOKUvienna HalberdC
By Dr. Priyom Bose, Ph.D.Nov 22 2022Reviewed by Benedette Cuffari, M.Sc. The rapid spread of the severe acute respiratory syndrome coronavirus 2 has resulted in the coronavirus disease 2019 pandemic.
Background Prophylactic and therapeutic monoclonal antibodies play an important role in protecting vulnerable groups from acquiring COVID-19. For example, vaccination does not effectively protect immunocompromised individuals from contracting SARS-CoV-2 infection, as they may not develop substantial and durable immunity post-vaccination.
Among the classes, Class 1 and 2 mAbs, which interact with the angiotensin-converting enzyme 2 binding site of the RBD, have greater neutralizing ability. It is important to characterize mAbs in these classes, as it helps in the development of effective mAb cocktails that reduce immune evasion. Plants are promising systems to produce recombinant proteins. One previous clinical study demonstrated that a newly formulated plant-based COVID-19 vaccine was safe and highly effective in preventing infection. Since then, this vaccine has received approval for human use in Canada.
Study findings The expression of chimeric 11D7 in ΔXFT Nicotiana benthamiana plants peaked within one week of agroinfiltration to around 131 µg of p11D7 per gram of fresh leaf weight . Although the level of 11D7 mAb produced in the plant system was promising, it was lower than mAbs produced in other optimized geminiviral vectors.
This value was comparable to other neutralizing mAbs against SARS-CoV-2, such as CA1 and CB6 that are produced in plants. Nevertheless, the 50% inhibitory concentration of p11D7 for neutralization of the ancestral SARS-CoV-2 strain was significantly higher than other plant-based mAbs at 25.37 µg/mL.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
The biological properties of the SARS-CoV-2 E protein in the context of HIV-1The biological properties of the SARS-CoV-2 E protein in the context of HIV-1 UnivOfKansas KUMedCenter SARSCoV2 COVID19 coronavirus covid HIV
Consulte Mais informação »
Potent hypervalent nanoparticles against HIV, Lassa and SARS-CoV-2 variantsIn a recent study published in the journal Advanced Science, researchers developed molecularly imprinted nanoparticles (nanoMIPs) with broad-spectrum activity against lethal viruses.
Consulte Mais informação »
Chitin-immobilized nanobodies for SARS-CoV-2 detectionChitin-immobilized nanobodies for SARS-CoV-2 detection medrxivpreprint HHU_de SARSCoV2 covid coronavirus COVID19 nanobodies
Consulte Mais informação »
What is the association between particulate matter exposure and SARS-CoV-2 infections?In a new study, researchers assessed the association between particulate matter ≤2.5mm (PM2.5) exposure and SARS-CoV-2 infection and severity outcomes such as hospitalizations and deaths.
Consulte Mais informação »
SARS-CoV-2 seroprevalence in domestic cats has increased over timeSARS-CoV-2 seroprevalence in domestic cats has increased over time biorxivpreprint UofGlasgow SARSCoV2 COVID19 DomesticCats Seroprevalence
Consulte Mais informação »